G. Le Fur

G. Le Fur, C. Serradeil-Le Gal, A. Barbier, 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Identification of binding sites for SR 46349B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain.

G. Fur, M. Rinaldi-Carmona, C. Congy, 1994, Life sciences.

Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.

P. Ferrara, G. Fur, D. Shire, 1999, European journal of pharmacology.

Histidine modification with diethylpyrocarbonate induces a decrease in the binding of an antagonist, PK 11195, but not of an agonist, RO5-4864, of the peripheral benzodiazepine receptors.

J. Bénavidès, G. Le Fur, A. Uzan, 1984, Life sciences.

Relationships between plasma corticosteroids and benzodiazepines in stress.

G. Le Fur, A. Uzan, N. Mitrani, 1979, The Journal of pharmacology and experimental therapeutics.

A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.

E. Naline, G. Néliat, J. Breliere, 1992, Life sciences.

Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.

P. Soubrié, M. Poncelet, C. Gueudet, 2002, Canadian journal of physiology and pharmacology.

In vitro characterization of tachykinin NK2‐receptors modulating motor responses of human colonic muscle strips

J. Maffrand, G. Le Fur, T. Croci, 1998, British journal of pharmacology.

Tachykinin-induced contractions of the guinea pig ileum longitudinal smooth muscle: tonic and phasic muscular activities.

J. Breliere, G. Le Fur, X. Emonds-alt, 1997, Canadian journal of physiology and pharmacology.

Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists

P. Casellas, J. Breliere, G. Le Fur, 1996 .

In vitro characterization of the non-peptide tachykinin NK1 and NK2-receptor antagonists, SR140333 and SR48968 in different rat and guinea-pig intestinal segments.

G. Le Fur, T. Croci, X. Emonds-alt, 1994, Life sciences.

The NK2 receptor antagonist SR48968 inhibits thalamic responses evoked by thermal but not mechanical nociception.

P. Soubrié, C. Gueudet, J. Breliere, 1993, European Journal of Pharmacology.

The NK1 receptor is involved in the neurokinin‐induced shape change of rabbit platelets

J. Herbert, G. Le Fur, P. Savi, 1992, FEBS letters.

Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.

J. Maffrand, M. Rinaldi-Carmona, G. Le Fur, 2002, European journal of pharmacology.

Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon.

J. Maffrand, M. Rinaldi-Carmona, G. Le Fur, 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

P. Ferrara, D. Caput, G. Fur, 1996, Biochimica et biophysica acta.

Cannabinoids enhance human B‐cell growth at low nanomolar concentrations

P. Casellas, G. Le Fur, J. Derocq, 1995, FEBS letters.

Characterization of two cloned human CB1 cannabinoid receptor isoforms.

P. Casellas, P. Ferrara, M. Rinaldi-Carmona, 1996, The Journal of pharmacology and experimental therapeutics.

Functional assessment of β adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle

J. Maffrand, G. Le Fur, T. Croci, 2000, Gut.

The rat β3‐adrenergic receptor gene contains an intron

M. Kaghad, D. Caput, G. Le Fur, 1993 .

Subcellular localization of peripheral benzodiazepine receptors on human leukocytes.

P. Casellas, G. Le Fur, P. Carayon, 1994, Laboratory investigation; a journal of technical methods and pathology.

A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1

P. Casellas, J. Maffrand, M. Rinaldi-Carmona, 1997, The Journal of Biological Chemistry.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

P. Soubrié, D. Gully, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization

P. Soubrié, M. Poncelet, J. Maruani, 2004, Journal of Pharmacology and Experimental Therapeutics.

Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors

J. Lélias, M. Kaghad, P. Chalon, 1993, FEBS letters.

On the regional and specific serotonin uptake inhibition by LM 5008.

G. Le Fur, A. Uzan, M. Kabouche, 1978, Life sciences.

Opposite effects of two ligands for peripheral type benzodiazepine binding sites, PK 11195 and RO5-4864, in a conflict situation in the rat.

G. Le Fur, A. Uzan, C. Renault, 1985, Life sciences.

Partial purification and pharmacology of peripheral-type benzodiazepine receptors.

G. Le Fur, A. Uzan, F. Bégassat, 1987, Journal of receptor research.

[Biotransformation of 10-(3-quinuclidinylmethyl)phenothiazine (LM 209), a new anti-allergy agent and the distribution and excretion of its metabolites].

G. Le Fur, A. Uzan, C. Gueremy, 1976, Xenobiotica; the fate of foreign compounds in biological systems.

[Prevention of experimental thrombosis of the coronary artery, in anesthetized dogs, with a low molecular weight heparin, enoxaparine (PK 10169)].

G. Le Fur, A. Uzan, M. Mestre, 1985, Annales pharmaceutiques francaises.

Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.

J. Simiand, P. Soubrié, G. Le Fur, 1993, Fundamental & clinical pharmacology.

Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug -mezilamine- with weak cataleptogenic properties.

G. Le Fur, A. Uzan, M. Kabouche, 1978, Life sciences.

[3H]spiroperidol binding on lymphocytes: changes in two different groups of schizophrenic patients and effect of neuroleptic treatment.

H. Lôo, É. Zarifian, G. Le Fur, 1983, Life sciences.

High-level production of a human membrane protein in yeast: the peripheral-type benzodiazepine receptor.

P. Ferrara, G. Le Fur, G. Loison, 1995, Gene.

3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.

G. Le Fur, A. Uzan, C. Gueremy, 1980, Journal of medicinal chemistry.

SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

B. Scatton, J. Maffrand, E. Naline, 2004, Journal of Pharmacology and Experimental Therapeutics.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.

J. Simiand, P. Soubrié, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.

D. Gully, G. Néliat, G. Le Fur, 1993, European journal of pharmacology.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors.

J. Bénavidès, G. Le Fur, A. Uzan, 1986, Journal of medicinal chemistry.

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

S. Galiègue, P. Casellas, G. Fur, 1995, European journal of biochemistry.

Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.

G. Griebel, P. Soubrié, M. Poncelet, 2001, Journal of Pharmacology and Experimental Therapeutics.

Neuronal NK3-receptors in guinea-pig ileum and taenia caeci: in vitro characterization by their first non-peptide antagonist, SR142801.

G. Le Fur, T. Croci, X. Emonds-alt, 1995, Life sciences.

Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies.

J. Bénavidès, G. Le Fur, A. Uzan, 1983, Life sciences.

Effects of 4-(3-indolyl-alkyl) piperidine derivatives on brain 5-hydroxytryptamine turnover and on cardiac and brain noradrenaline or 5-hydroxytryptamine depletion induced by 6-hydroxydopamine, H 75/12 and 4-chloroamphetamine.

G. Le Fur, A. Uzan, N. Mitrani, 1977, Biochemical pharmacology.

Study of two new non-steroid anti-inflammatory drugs having a pyrazole structure (LM 22070 and LM 22102).

G. Le Fur, A. Uzan, J. Mizoule, 1979, Archives internationales de pharmacodynamie et de therapie.

Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24.

P. Casellas, D. Gully, J. Monroe, 1996, The Biochemical journal.

Molecular cloning of a levocabastine‐sensitive neurotensin binding site

P Ferrara, M. Kaghad, P. Chalon, 1996, FEBS letters.

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

P Ferrara, P. Soubrié, P. Casellas, 1998, European journal of pharmacology.

The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae

M. Kaghad, P. Ferrara, D. Caput, 1996, Molecular and cellular biology.

Cloning and Characterization of PRAX-1

S. Galiègue, P. Casellas, G. Le Fur, 1999, The Journal of Biological Chemistry.

Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease

Y. Agid, A. Bonnet, M. Welter, 2004, Clinical neuropharmacology.

Effect of mequitazine a non sedative antihistamine on brain H1 receptors.

G. Le Fur, A. Uzan, C. Malgouris, 1981, Life sciences.

Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1996, European journal of biochemistry.

Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells.

P. Casellas, D. Shire, G. Le Fur, 1993, Life sciences.

Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor

P Ferrara, M. Kaghad, P. Chalon, 1993, FEBS letters.

Characterization of a peripheral‐type benzodiazepine‐binding site in the mitochondria of Chinese hamster ovary cells

P. Ferrara, G. Le Fur, J. Riond, 1989, FEBS letters.

Cardiac beta-adrenergic receptor: evaluation of FM 24 as a new and very slowly dissociable blocker.

J. Hanoune, G. Le Fur, A. Uzan, 1978, Life sciences.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

CB1 receptor‐mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus

M. Maftouh, B. Scatton, G. Le Fur, 2007, The European journal of neuroscience.

Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.

P. Soubrié, G. Fur, G. Le Fur, 1996, Life sciences.

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1998, The Journal of pharmacology and experimental therapeutics.

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

S. Heishman, K. Preston, M. Huestis, 2007, Psychopharmacology.

Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor

Pierre Casellas, P. Casellas, G. Le Fur, 2003, Journal of Biological Chemistry.

Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.

P. Casellas, L. Fajas, G. Le Fur, 2005, European journal of pharmacology.

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

P. Soubrié, F. Oury-Donat, J. Maffrand, 2003, Molecular pharmacology.

Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1998, The Journal of pharmacology and experimental therapeutics.

Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.

P. Soubrié, G. Fur, M. Rinaldi-Carmona, 1996, Life sciences.

Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716

P. Soubrié, J. Terranova, M. Rinaldi-Carmona, 1996, Psychopharmacology.

Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.

P Ferrara, P. Ferrara, M. Rinaldi-Carmona, 2000, European journal of pharmacology.

Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

P. Soubrié, M. Poncelet, J. Breliere, 1999, Psychopharmacology.

Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.

S. Stahl, G. Griebel, J. Stemmelin, 2008, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain.

P. Ferrara, D. Caput, A. Coquerel, 1995, Brain research. Molecular brain research.

Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor.

M. Mattei, M. Kaghad, X. Dumont, 1991, European journal of biochemistry.

Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors.

X. Langlois, J. Simiand, P. Soubrié, 1992, European journal of pharmacology.

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

P. Soubrié, D. Gully, R. Boigegrain, 1997, The Journal of pharmacology and experimental therapeutics.

In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747.

P. Casellas, G. Le Fur, B. Bourrie, 1995, The Journal of pharmacology and experimental therapeutics.

Photoaffinity labeling of peripheral-type benzodiazepine-binding sites.

G. Le Fur, A. Uzan, C. Renault, 1987, Molecular pharmacology.

Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities.

J. Herbert, G. Le Fur, F. Bono, 1999, Biochemical and biophysical research communications.

Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864.

P Ferrara, P. Ferrara, D. Caput, 1994, Molecular pharmacology.

Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies.

G. Le Fur, A. Uzan, F. Imbault, 1983, Life sciences.

Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats

J. Maffrand, G. Le Fur, T. Croci, 1997, British journal of pharmacology.

Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin.

D. Gully, M. Canton, W. Rostène, 1996, Life sciences.

Stereospecificity of the in vitro and in vivo blockade of beta-receptors by FM 24, a slowly reversible ligand.

G. Le Fur, A. Uzan, T. Canton, 1981, Life sciences.

Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.

J. Simiand, P. Soubrié, F. Oury-Donat, 1993, Molecular pharmacology.

Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.

J. Herbert, G. Le Fur, P. Schaeffer, 1995, The American journal of physiology.

Blockade of Neurotensin Receptor by SR 48692 Potentiates the Facilitatory Effect of Haloperidol on the Evoked In Vivo Dopamine Release in the Rat Nucleus Accumbens

P. Soubrié, R. Steinberg, G. Le Fur, 1995, Journal of neurochemistry.

Quantitative Autoradiography of [3H]Indalpine Binding Sites in the Rat Brain: I. Pharmacological Characterization

H. Savaki, G. Le Fur, A. Uzan, 1985, Journal of neurochemistry.

Opposite effects of an agonist, RO5-4864, and an antagonist, PK 11195, of the peripheral type benzodiazepine binding sites on audiogenic seizures in DBA/2J mice.

G. Le Fur, A. Uzan, C. Renault, 1984, Life sciences.

Expression and pharmacological characterization of the human peripheral-type benzodiazepine receptor in yeast.

P. Ferrara, D. Caput, G. Fur, 1991, European journal of pharmacology.

Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists

P. Casellas, J. Breliere, G. Le Fur, 1996, FEBS letters.

Pharmacological Characterization of Tachykinin Receptors Controlling Acetylcholine Release from Rat Striatum: An In Vivo Microdialysis Study

P. Soubrié, R. Steinberg, J. Souilhac, 1995, Journal of neurochemistry.

Decrease in lymphocyte [3H]spiroperidol binding sites in Parkinsonism.

M. Baulac, V. Meininger, G. Le Fur, 1980, Life sciences.

Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins.

G. Le Fur, R. Cecchi, T. Croci, 1996, British journal of pharmacology.

Multiple benzodiazepine receptors: evidence of dissociation between anticonflict and anticonvulsant properties by PK 8165 and PK 9084 (two quinoline derivatives).

M. Héaulme, G. Le Fur, A. Uzan, 1981, Life sciences.

[Effects of indalpin, a specific 5-HT uptake inhibitor, on the ethanol behavioral dependence and on the voluntary ethanol consumption in rat (author's transl)].

G. Le Fur, A. Uzan, G. Aufrère, 1981, Annales pharmaceutiques francaises.

Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.

J. Simiand, P. Soubrié, M. Rinaldi-Carmona, 1992, The Journal of pharmacology and experimental therapeutics.

Characterization of solubilized "peripheral type" benzodiazepine binding sites from rat adrenals by using [3H]PK 11195, an isoquinoline carboxamide derivative.

G. Le Fur, A. Uzan, C. Renault, 1985, Biochemical pharmacology.

Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.

P. Soubrié, S. Galiègue, P. Casellas, 2002, Molecular pharmacology.

Involvement of cortical neurotensin in the regulation of rat meso‐cortico‐limbic dopamine neurons: Evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade

P. Soubrié, C. Gueudet, R. Steinberg, 1997, Synapse.

Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex

P. Soubrié, G. Le Fur, P. Keane, 1999, British journal of pharmacology.

Platelet monoamine oxidase activity and plasma 3,4-dihydroxyphenylethylene glycol levels during the menstrual cycle.

H. Lôo, B. Scatton, G. Le Fur, 1985, Neuropsychobiology.

Evidence for an increase in [3H]spiperone binding in hypothalamic nuclei during the development of spontaneous hypertension in the rat.

G. Le Fur, A. Uzan, F. Guilloux, 1983, Clinical and experimental hypertension. Part A, Theory and practice.

SR 48692 inhibits neurotensin-induced [3H]dopamine release in rat striatal slices and mesencephalic cultures.

D. Gully, M. Héaulme, R. Leyris, 1994, European journal of pharmacology.

Circadian rhythm in the membrane of circulating human blood cells: microviscosity and number of benzodiazepine binding sites. A search for regulation by plasma ions, nucleosides, proteins or hormones.

J. Sulon, F. Lévi, Y. Touitou, 1987, Chronobiology international.

In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist.

P. Soubrié, M. Héaulme, R. Steinberg, 1993, European journal of pharmacology.

Molecular basis for the different binding properties of benzodiazepines to human and bovine peripheral‐type benzodiazepine receptors

P. Ferrara, D. Caput, D. Shire, 1993, FEBS letters.

Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor.

J. Herbert, J. Maffrand, G. Le Fur, 1992, The Journal of pharmacology and experimental therapeutics.

Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression

G. Griebel, P. Soubrié, J. Stemmelin, 2004 .

Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors

M. Kaghad, P. Chalon, P. Ferrara, 1993, FEBS letters.

Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus.

L. Bankir, G. Le Fur, N. Bouby, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

In vitro functional evidence of different neurotensin‐receptors modulating the motor response of human colonic muscle strips

P. Chalon, P. Ferrara, J. Maffrand, 1999, British journal of pharmacology.

Blockade of neurokinin3 receptors antagonizes drug‐induced population response and depolarization block of midbrain dopamine neurons in guinea pigs

P. Soubrié, C. Gueudet, G. Le Fur, 1999, Synapse.

Pharmacology of peripheral type benzodiazepine receptors in the heart.

G. Le Fur, A. Uzan, C. Renault, 1985, Progress in clinical and biological research.

Characterization of peripheral type benzodiazepine binding sites in human and rat platelets by using [3H]PK 11195. Studies in hypertensive patients.

G. Le Fur, A. Uzan, P. Plouin, 1984, Biochemical pharmacology.

The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat.

P. Soubrié, C. Gueudet, M. Rinaldi-Carmona, 1995, Neuroreport.

Facilitating effects of SR 57746A on short‐term memory in an operant delayed alternation task in aged rats

P. Soubrié, R. Porsolt, G. Le Fur, 1995 .

G. Griebel, J. Simiand, P. Soubrié, 2002, Journal of Pharmacology and Experimental Therapeutics.